Published in Lancet on July 13, 2002
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer (AADLPC) | NCT02175212
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer | NCT04243473
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys (2007) 3.87
Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol (2009) 3.86
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst (2006) 3.10
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. J Clin Oncol (2015) 2.71
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys (2014) 2.21
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.92
Reduction in physician reimbursement and use of hormone therapy in prostate cancer. J Natl Cancer Inst (2010) 1.91
Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res (2008) 1.85
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer (2005) 1.68
The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur J Nucl Med Mol Imaging (2010) 1.62
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int (2006) 1.58
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol (2006) 1.56
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol (2015) 1.55
Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol (2012) 1.55
Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer (2008) 1.53
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest (2011) 1.46
Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. Br J Cancer (2015) 1.46
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol (2016) 1.45
Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology (2011) 1.44
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol (2006) 1.38
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer (2007) 1.28
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol (2009) 1.22
Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol (2009) 1.20
Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol (2010) 1.19
What's a man to do? Treatment options for localized prostate cancer. Can Fam Physician (2004) 1.18
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.14
Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol (2013) 1.13
CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res (2010) 1.12
Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol (2006) 1.12
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol (2014) 1.06
Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.05
Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol (2007) 1.05
Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Neoplasia (2007) 1.05
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer (2013) 1.05
Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer (2011) 1.04
Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol (2010) 1.04
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer (2014) 1.04
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med (2009) 1.03
Surgery vs. radiotherapy in localized prostate cancer. Which is best? Radiat Oncol (2008) 1.03
Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int J Radiat Oncol Biol Phys (2007) 1.01
Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl (2012) 0.98
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists. Can Urol Assoc J (2011) 0.97
Bone health and prostate cancer. Prostate Cancer Prostatic Dis (2009) 0.97
Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.96
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest (2013) 0.96
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer (2005) 0.96
Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer Prostatic Dis (2009) 0.95
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther (2009) 0.95
Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Radiat Oncol (2012) 0.95
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer (2010) 0.94
Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer (2011) 0.94
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol (2009) 0.91
Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys (2011) 0.91
Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw (2010) 0.90
Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl (2015) 0.90
Is there a role for chemotherapy in prostate cancer? Br J Cancer (2004) 0.89
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. Int J Radiat Oncol Biol Phys (2012) 0.89
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer (2012) 0.89
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol (2008) 0.89
The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer (2012) 0.89
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging (2009) 0.88
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol (2010) 0.88
Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. World J Urol (2012) 0.88
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys (2015) 0.87
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res (2013) 0.87
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys (2013) 0.87
Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol (2012) 0.87
Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr (2012) 0.87
Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res (2012) 0.87
Estrogenic side effects of androgen deprivation therapy. Rev Urol (2007) 0.87
Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey. Pract Radiat Oncol (2012) 0.86
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS One (2015) 0.86
Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer. Onco Targets Ther (2014) 0.86
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med (2006) 12.50
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol (2007) 7.51
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med (2007) 6.55
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2010) 6.15
Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med (2009) 5.82
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med (2015) 5.08
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol (2006) 4.36
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol (2005) 3.31
Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol (2009) 3.16
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol (2007) 2.90
Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med (2003) 2.88
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med (2003) 2.76
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol (2002) 2.63
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol (2004) 2.29
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol (2009) 2.26
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Utility of serum tumor markers during surveillance for stage I seminoma. Cancer (2012) 2.05
The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review. Radiother Oncol (2002) 2.04
What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer? BJU Int (2006) 2.03
Information needs of men on androgen deprivation therapy. BJU Int (2011) 2.02
Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer (2003) 2.01
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Innovations in image-guided radiotherapy. Nat Rev Cancer (2007) 1.98
Guidelines on bladder cancer. Eur Urol (2002) 1.97
Predictive model for survival in patients with advanced cancer. J Clin Oncol (2008) 1.93
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol (2008) 1.88
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol (2009) 1.81
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol (2011) 1.76
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res (2007) 1.75
Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys (2002) 1.67
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol (2010) 1.66
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol (2006) 1.64
Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int (2009) 1.62
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer (2008) 1.61
Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer (2008) 1.58
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys (2005) 1.54
Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol (2002) 1.52
The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol (2004) 1.51
Ratios of involved nodes in early breast cancer. Breast Cancer Res (2004) 1.50
Treatment options, prognostic factors and selection of treatment in stage I seminoma. Onkologie (2006) 1.49
Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer (2007) 1.48
Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys (2007) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys (2008) 1.41
Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. J Clin Oncol (2007) 1.41
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res (2012) 1.41
A (short) history of image-guided radiotherapy. Radiother Oncol (2008) 1.40
Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys (2010) 1.39
Preoperative concomitant hyperfractionated radiotherapy and gemcitabine for locally advanced rectal cancers: a phase I-II trial. Cancer J (2005) 1.38
A dose-volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to 'prostate alone'. Clin Oncol (R Coll Radiol) (2002) 1.37
Robot-assisted cystectomy: does it meet expectations? Eur Urol (2010) 1.37